Why the study?
Does eplerenone added to optimal medical therapy reduce morbidity and mortality in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure?
Does eplerenone added to optimal medical therapy reduce morbidity and mortality in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure?
Eplerenone added to optimal medical therapy reduces morbidity and mortality in patients with acute MI complicated by LV dysfunction and heart failure.
No takes yet. Share an insight, caveat, or question.
Supports eplerenone addition in acute MI with LV dysfunction and HF; confirms morbidity and mortality benefit on optimal therapy.
Pitt et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: